Share on
Order Skyrizi (risankizumab)
|
11 views
Box
Negotiable
MOQ:
10 Box
Payment Term:
Money Gram, T/T, W/U
Trade Term:
CIF
Port Of Loading:
Guangzhou, China, Cn (GZH/CAN)
Key Takeaways
Freshdi AI is analyzing this product...
Skyrizi Subcutaneous Injection
Skyrizi Once Every 8 Weeks
Targeted Immune Modulation Skyrizi
Product Specifications
Indication:
Moderate To Severe Plaque Psoriasis, Psoriatic Arthritis, And Ulcerative Colitis
Dosage Frequency:
Once Every 8 Weeks
Material:
Other
Packaging Properties:
Reusable Packaging, Single-Use Packaging
Clinical Efficacy:
Significant Improvement In Skin Lesions, Joint Pain, And Gastrointestinal Symptoms
Route Of Administration:
Subcutaneous Injection
Therapeutic Approach:
Targeted Immune Modulation
Mechanism Of Action:
Targets Interleukin-23 (il-23) To Reduce Inflammation
3.9
France
Distribution / Wholesale, Exporter/Wholesaler, Food manufacturing
France
Activity signals
Avg Response Time
≤ 24h
Response Rate
55%
Inquiry Open Rate
86%
Total inquiries received
29
Export Markets
Based on the information provided by the supplier.
Australia
Austria
Aruba
Armenia
Argentina
Central America & Caribbean
24%
Western Europe
24%
Oceania
22%
Eastern Europe
17%
East Africa
13%
Verification information
Verify business documents
By Freshdi Verification System
Verify phone number
Buyer Verification Team
Verify account email
By Freshdi.com
Verify work email
Product descriptions from the supplier
Skirizi (Risankizumab)
Product Overview
Skirizi (risankizumab) is a biologic medication indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ulcerative colitis. It is a human monoclonal antibody that targets interleukin-23 (IL-23), helping to reduce inflammation and control disease symptoms.
Key Features
Skirizi is administered via subcutaneous injection and is designed to provide targeted immune modulation. It has demonstrated significant improvement in skin lesions, joint pain, and gastrointestinal symptoms in clinical studies. The treatment is typically prescribed for patients who have not responded adequately to other therapies.
Usage and Administration
Skirizi is administered once every 8 weeks. The dosage and frequency are determined by the patient’s condition and response to treatment. It is important to follow the prescribed regimen to achieve optimal outcomes.
User Reviews
No reviews yet
Be the first to share your experience - your feedback helps other buyers trade with confidence.
Related searches
You are viewing details for Order Skyrizi (risankizumab). The information provided here is either posted directly by the supplier, who is responsible for its accuracy, or collected by Freshdi AI from publicly available sources. Freshdi strives to make product information as useful and reliable as possible, but we do not guarantee complete accuracy. If you notice any incorrect or misleading details, please use the Report Product option so our team can review and address it quickly.
